Non-coding RNA and its network in the pathogenesis of Myasthenia Gravis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39318549/
Myasthenia Gravis (MG) is a chronic autoimmune disease that primarily affects the neuromuscular junction, leading to muscle weakness in patients with this condition. Previous studies have identified several dysfunctions in...
Noncoding RNAs, including miRNA, lncRNA, and circRNA, are key regulators in myasthenia gravis, impacting thymus and PBMC dysfunctions, with potential as biomarkers for diagnosis and therapeutic targets.
A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38726639/
Telitacicept demonstrated safety, good tolerability and reduced clinical severity throughout the study period. Further validation of the clinical efficacy of telitacicept in gMG will be conducted in an upcoming phase...
Telitacicept showed safety, tolerability, and clinical efficacy in reducing disease severity in patients with generalized myasthenia gravis, with significant improvements in QMG scores over 24 weeks.
Myocarditis, Myositis, and Myasthenia Gravis Overlap Syndrome Associated with Immune Checkpoint Inhibitors: A Systematic Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39202282/
Immune checkpoint inhibitors (ICIs) have significantly transformed cancer treatment, but their use is linked to immune-related adverse events (irAEs), including the rare ICI-associated myocarditis, myositis, and myasthenia gravis (MMM) overlap...
MMM overlap syndrome, a rare but severe complication of immune checkpoint inhibitors, requires urgent recognition and corticosteroid treatment due to high mortality, especially in cancer patients receiving ICIs.
Treating myasthenia gravis beyond the eye clinic - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38789789/
Myasthenia gravis (MG) is one of the most well characterised autoimmune disorders affecting the neuromuscular junction with autoantibodies targeting the acetylcholine receptor (AChR) complex. The vast majority of patients present...
Myasthenia gravis is an autoimmune disorder affecting neuromuscular junctions, causing muscle weakness, often starting with ocular symptoms. Management includes cholinesterase inhibitors, immunosuppressants, and evolving therapies targeting immune components.
Does Surgical Removal of the Thymus Have Deleterious Consequences?
Source : https://pubmed.ncbi.nlm.nih.gov/38781559/
The role of immunosenescence, particularly the natural process of thymic involution during aging, is increasingly acknowledged as a factor contributing to the development of autoimmune diseases and cancer. Recently, a...
Thymectomy benefits in MG and thymoma patients outweigh long-term cancer and autoimmunity risks, but incidental thymic removal during other surgeries should be minimized.